CA2494061A1 — Protein tyrosine kinase inhibitors
Assigned to Cotinga Pharmaceuticals Inc · Expires 2004-02-05 · 22y expired
What this patent protects
The present invention relates to compounds of the Formula (I), the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to tr…
USPTO Abstract
The present invention relates to compounds of the Formula (I), the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals. In said Formula (I), : n is an integer, preferably n is 1; R1 and R2 are independently selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h), (i) and (j).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.